Biotechnology

Indaptus Therapeutics

Indaptus Therapeutics released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2319 (forecast USD -1.87)

Indaptus Therapeutics released FY2025 Annual Earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -21.5799 (forecast USD -25.44)

Indaptus Therapeutics released FY2025 Q4 earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.5145 (forecast USD -4.36)

Indaptus Therapeutics released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -21.0779

Indaptus Therapeutics released FY2025 Q3 earnings on November 12, 2025 (EST), with actual revenue of USD 0 and EPS of USD -2.9839 (forecast EPS was USD -4.17)

Indaptus Therapeutics released FY2025 Semi-Annual Earnings on August 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -18.092

Indaptus Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.0949 (forecast USD -9.24)

Indaptus Therapeutics Raises $5.7 Million

Indaptus Therapeutics Successfully Sells $2.3 Million Convertible Notes and Warrants

Indaptus Therapeutics Launches Clinical Trial for Decoy20 and Tislelizumab Combination Therapy

Indaptus Therapeutics Inc. narrows losses and reaches key milestones in Q1

Indaptus Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.999 (forecast USD -5.04)

Indaptus Therapeutics Reports Narrowed EPS Loss in Q1 2025

Indaptus Therapeutics released FY2024 Q4 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -10.5875 (forecast USD -13.1599)

Indaptus Therapeutics released FY2024 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -44.9582 (forecast USD -47.8799)

Indaptus Therapeutics Announces $13.5 Million Registered Direct Offering and Concurrent Private Placement

Maxim Group Adjusts Rating for Indaptus Therapeutics

Indaptus Therapeutics released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.0356 (forecast USD -13.4399)

Indaptus Therapeutics released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -34.8196

Indaptus Therapeutics released FY2024 Semi-Annual Earnings on August 12, 2024 (EST) with actual revenue of USD 0 and EPS of USD -25.7864

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

Vida Global

BiomX

MicroAlgo

MetaVia

Quantum Cyber NV

INDP

Earnings Watch

Indaptus Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Indaptus Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

TRAW

BTAI

SBIO

On May 15, 2026, several companies are set to report their first-quarter earnings. Notable reports include Traws Pharma, Indaptus Therapeutics, and Metropolitan Bank Holding, which is expected to report earnings of $0.40 per share. Other companies like BioXcel Therapeutics and A2Z Cust2Mate Solutions are projected to report losses. The earnings reports will provide insights into the financial performance of these firms.

benzinga_article

Traws Pharma

Metropolitan Bank

Bioxcel Therap

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares US Pharma

Satellos Bioscience

Purple Biotech

Instil Bio

Mastech Digital

Veea

New Era Energy & Digital

Empire Petroleum

H World

Seritage Growth Properties-A Reit

American Strategic Investment

A2Z Cust2Mate Solutions

ARS Pharmaceuticals

Suncrete

Sigma Lithium

Lument Finance Trust

LM Funding America

Creative Realities

Digi Power X

Lifeward

SurgePays

MiNK Therapeutics

Edible Garden AG

Super League Enterprise

Data Storage

Venu

Arrive AI

Liberty All Star Eq Fd

Americas Gold and Silver

RBC Bearings

PAVmed

Datavault AI

Beam Global

SentinelOne

Banzai

Cloudastructure

Skillz

BioCardia

Lantern Pharma

Solana

Nuvve

Flexible Solutions

Veea - CW28

NEW ERA ENERGY & DIGITAL INC. C/WTS 06/12/2029(TO PR COM)

HWORLD-S

EDIBLE GARDEN AG INC C/WTS (TO PUR COM)

DATA STORAGE CORP C/WTS 18/05/2026 (TO PUR COM)

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

BANZAI INTERNATIONAL INC C/WTS 14/12/2028 (TO PUR COM)

NUVVE Holdings - CW26

Earnings Scheduled For May 15, 2026

ARKG

LABU

IBBQ

Indaptus Therapeutics reported its Q1 2026 financial results, showing a net loss of $2.5 million, down from $4.5 million in Q1 2025. The company is undergoing executive management changes and evaluating its development programs. Research and development expenses decreased to $0.5 million, while general and administrative expenses were $1.7 million. The company has $1.5 million in cash and needs to raise additional capital. All preferred stock has been converted to common stock.

StockTitan

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | INDP Stock News

ESPR

In Friday's pre-market session, Cue Biopharma saw a significant gain of 90.1%, reaching $28.02, while Esperion Therapeutics rose by 57% to $3.14. Other notable gainers included Akanda (+30.26%), Psyence Biomedical (+19.11%), and iSpecimen (+17.2%). Conversely, Akari Therapeutics dropped 25.9% to $4.00, with Senseonics Holdings and Rein Therapeutics also experiencing declines. Summit Therapeutics fell by 20.55% to $17.05, and Sotera Health decreased by 10.75% to $13.89. Q1 earnings reports were released recently for several companies.

Esperion Therap

Cue BioPharma

SPDR S&P Health Equip

iShares US Healthcare Providers

VG Health

iShares Global Healthcare

iShares US Medical Devices

Akanda

Psyence Biomedical

iSpecimen

Cerus

Akari Therap

Senseonics

Rein Therapeutics

Summit Therapeutics

Sotera Health

Crescent Biopharma

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

12 Health Care Stocks Moving In Friday's Pre-Market Session

Indaptus Therapeutics has appointed Tim Ruan and Yi Zhang as independent directors, effective April 22, 2026, while Matthew McMurdo has resigned from the board on the same date. Ruan, a financial executive and CFO of Ocumension Therapeutics, will serve on the Audit Committee, while Zhang, an IP and life sciences expert, will join the Nominating Committee. McMurdo's resignation was not due to any disagreements with the company.

TradingView

Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns